Neuroendocrine Tumor Treatment

ABSTRACT

A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.

The present invention relates to organic compounds, more specifically tothe use of mTOR inhibitors in neuroendocrine tumor treatment.

An mTOR inhibitor as used herein is a compound which targetsintracellular mTOR (“mammalian Target of rapamycin”). mTOR is a familymember of phosphatidylinositol 3-kinase(P13-kinase) related kinase. Thecompound rapamycin and other mTOR inhibitors inhibit mTOR activity via acomplex with its intracellular receptor FKBP12 (FK506-binding protein12). mTOR modulates translation of specific mRNAs via the regulation ofthe phosphorylation state of several different translation proteins,mainly 4E-PB1, P70S6K (p70S6 kinase 1) and eEF2.

Rapamycin is a known macrolide antibiotic produced by Streptomyceshygroscopicus of formula

Other mTOR inhibitors include rapamycin derivatives, for exampleincluding rapamycin substituted in position 40 and/or 16 and/or 32.

Examples of other mTOR inhibitors include 40-O-alkyl-rapamycinderivatives, e.g. 40-O-hydroxyalkyl-rapamycin derivatives, for example40-O-(2-hydroxy)-ethyl-rapamycin (everolimus),

rapamycin derivatives which are substituted in 40 position byheterocyclyl, e.g. 40-epi-(tetrazolyl)-rapamycin (also known as ABT578),32-deoxo-rapamycin derivatives and 32-hydroxy-rapamycin derivatives,such as 32-deoxorapamycin,16-O-substituted rapamycin derivatives such as16-pent-2-ynyloxy-32-deoxorapamycin, 16-pent-2-ynyloxy-32(S orR)-dihydro-rapamycin, or 16-pent-2-ynyloxy-32(S orR)-dihydro-40-O-(2-hydroxyethyl)-rapamycin,rapamycin derivatives which are acylated at the oxygen in position 40,e.g. 40-[3-hydroxy-2-(hydroxy-methyl)-2-methylpropanoate]-rapamycin(also known as CCI779 or temsirolimus), rapamycin derivatives (alsosometimes designated as rapalogs) as disclosed in WO9802441 orWO0114387, e.g. including AP23573, such as40-O-dimethylphosphinyl-rapamycin, compounds disclosed under the namebiolimus (biolimus A9), including 40-O-(2-ethoxy)ethyl-rapamycin, andcompounds disclosed under the name TAFA-93, AP23464, AP23675 or AP23841;ormTOR inhibitors as e.g. disclosed in WO2004101583, WO9205179, WO9402136,WO9402385 and WO9613273.

Preferred mTOR inhibitors include

-   rapamycin, and/or-   40-O-(2-hydroxyethyl)-rapamycin, and/or-   32-deoxorapamycin, and/or-   16-pent-2-ynyloxy-32-deoxorapamycin, and/or-   16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, and/or-   16-pent-2-ynyloxy-32 (S or    R)-dihydro-40-0-(2-hydroxyethyl)-rapamycin, and/or-   40-[3-hydroxy-2-(hydroxy-methyl)-2-methylpropanoate]-rapamycin (also    known as CCI779) and/or-   40-epi-(tetrazolyl)-rapamycin (also known as ABT578), and/or-   the so-called rapalogs, e. g. as disclosed in WO9802441, WO0114387    and WO0364383, AP23573, AP23464, AP23675 or AP23841, e.g. AP23573,    and/or-   compounds disclosed under the name TAFA-93, and/or-   compounds disclosed under the name biolimus.

More preferably an mTOR inhibitor is selected from the group consistingof

-   rapamycin, and/or-   40-O-(2-hydroxyethyl)-rapamycin, and/or-   32-deoxorapamycin, and/or-   16-pent-2-ynyloxy-32-deoxorapamycin, and/or-   16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, and/or-   16-pent-2-ynyloxy-32 (S or    R)-dihydro-40-0-(2-hydroxyethyl)-rapamycin, and/or-   40-[3-hydroxy-2-(hydroxy-methyl)-2-methylpropanoate]-rapamycin (also    known as CCI779) and/or-   40-epi-(tetrazolyl)-rapamycin (also known as ABT578), and/or-   AP23573,-   such as 40-O-(2-hydroxyethyl)-rapamycin.

mTOR inhibitors, on the basis of observed activity, have been found tobe useful e. g. as immunosuppressant, e. g. in the treatment of acuteallograft rejection and have additionally potent antiproliferativeproperties which make them useful for cancer chemotherapy, particularlyfor the treatment of solid tumors, especially of advanced solid tumors.

Endocrine, e.g. neuroendocrine tumors (NETS), are found in the endocrinesystem. Carcinoid tumors, are a special type of tumor, generallyclassified as endocrine tumors. Carcinoid tumors belong to the family ofneuroendocrine tumors which derive from the neuroendocrine cell system.In the intestinal tract, these tumors develop deep in the mucosa,growing slowly and extending into the underlying submucosa and mucosalsurface. This results in the formation of small firm nodules, whichbulge into the intestinal lumen. Pancreatic neuroendocrine tumors (isletcell tumors), which were formerly classified as APUDomas (tumors of theamine precursor uptake and decarboxylation system), comprise less thanhalf of all neuroendicrine tumors and only 1-2% of all pancreatictumors. Pancreatic NETs can arise either in the pancreas (insulinomas,glucagonomas, nonfunctioning pancreatic NETs, pancreatic NETs causinghypercalcemia) or at both pancreatic and extrapancreatic sites(gastrinomas, ViPomas, somatostatinomas, GRFomas). The hormones secretedby pancreatic NETs depend upon the cell of origin and arephysiologically involved in a network of autocrine, paracrine, endocrineand neurotransmitter communication. While hormone secretion is notobserved in all cases of pancreatic NET, the apparently “nonfunctioning”(i.e., non-secreting) pancreatic NETs tend to be more aggressive andpresent with symptoms of tumor bulk (see e.g. Barakat et al,Endocrine-related cancer 2004; 11:1-18 and Tomassetti et al, Ann Oncol2001; 12(Suppl 2):S95-S99).

All pancreatic NETs, with the exception of 90% of insulinomas, havelong-term metastatic potential. Most are overtly malignant at the timeof diagnosis, and 60% or more present with liver metastases. The mostcommon cause of death from pancreatic NET is hepatic failure (WarnerRRP, Gastroenterology 2005; 128:1668-16842005).

In a recent review, the 5-year survival rate in a series of 83consecutive patients with pancreatic NETs has been reported to be 55.3%which points to an unmet medical need for continued treatment inpatients with pancreatic NETs whose disease has progressed following 1or more courses of chemotherapy.

Carcinoid tumors have historically been classified, according to theirpoint of origin in embryonic development, as arising from the foregut(e.g., bronchial, pulmonary or gastric carcinoid), midgut (e.g., smallintestine or appendiceal carcinoid), or hindgut (e.g., rectalcarcinoid), see e.g. Kulke M., Cancer Treatment Reviews 2003;29:363-370.

Primary foregut tumors are confined to the thymus, lung, stomach, andduodenum.

Midgut carcinoids are located in the distal ileum, cecum, and proximalcolon. One interesting subset of this group is appendiceal carcinoids,which are often benign and rarely give rise to metastatic disease. Themidgut carcinoids dominate the malignant carcinoid tumors, particularlywhen the carcinoid syndrome is present.

The hindgut tumors are primarily located in the distal colon and rectum.

Data suggest that the incidence of pulmonary and gastric carcinoid hasincreased in the past two decades.

According to histopathologic criteria, carcinoids can be divided intotypical (TC) and atypical (AC) carcinoids. Carcinoids can be placed in aspectrum of neuroendocrine tumors, ranging from low-grade malignant TCto intermediate AC to high-grade large-cell neuroendocrine carcinoma andsmall-cell lung carcinoma.

Carcinoid lung tumors e.g. include neuroendocrine carcinoma, Kulchitskycell carcinoma (KCC), bronchial carcinoid tumors, bronchial adenomas,typical carcinoids, atypical carcinoids, carcinoid syndrome, small-cellcarcinomas, Kulchitsky cells, argentaffin cells, pulmonary carcinoids,neuroendocrine lung tumors, (primary) pulmonary neoplasms,bronchopulmonary carcinoid tumors, lung neoplasms, lung cancers,pulmonary cancers, intrabronchial mass.

Bronchial carcinoid tumors may originate from the neurosecretory cellsof bronchial mucosa and were previously classified as bronchialadenomas. Bronchial carcinoids are now classed as low-grade malignantneoplasms because of their potential to cause local invasion, theirtendency for local recurrence, and their occasional metastases toextrathoracic sites. Bronchial carcinoids belong to a group ofneuroendocrine tumors, which cover a range of tumors ranging frombronchial carcinoid at one of the spectrum, with a small cell carcinoma,or possibly large cell neuroendocrine tumors at the other end. Theydemonstrate a wide range of clinical and biologic behaviors, includingthe potential to synthesize and secrete peptide hormones andneuroamines, particularly adrenocorticotropic hormone (ACTH), serotonin,somatostatin, and bradykinin.

Bronchial carcinoid tumors may arise from Kulchitsky cells (argentaffincells) within the bronchial mucosa. The predominant distribution ofcells are believed to occur at the bifurcation of the lobar bronchi.These cells are neurosecretory cells, which belong to the amineprecursor uptake and decarboxylation (APUD) system. They have thecapacity to synthesize serotonin (5-hydroxytryptamine),5-hydroxytryptophan, ACTH, norepinephrine, bombesin, calcitonin,antidiuretic hormone (ADH), and bradykinin.

Large-cell neuroendocrine carcinoma of the lung is a newly recognizedclinicopathologic entity, which is distinct from small-cell carcinomaand has a poor prognosis.

Typical carcinoid tumors of the lung represent the most welldifferentiated and least biologically aggressive type of pulmonaryneuroendocrine tumor. These tumors characteristically grow slowly andtend to metastasize infrequently. Atypical carcinoid tumors have a moreaggressive histologic and clinical picture. They metastasize at aconsiderably higher rate than do typical carcinoid tumors. Carcinoidsyndrome has been reported in association with very largebronchopulmonary carcinoid tumors or in the presence of metastaticdisease. It is noted much less frequently in association with carcinoidsof pulmonary origin than those originating within the gastrointestinaltract. Endocrine syndromes found in association with small cellcarcinoma of the lung are found less commonly with carcinoid tumors ofthe lung; however, some endocrine abnormalities have been attributed toboth typical and atypical pulmonary carcinoid tumors.

Carcinoid tumors of the GI tract may display an aggressive biologysimilar to that of adenocarcinomas, particularly when they are locatedin the colon, stomach, and small intestine, see e.g. Modlin I M et al,Gastroenterology 2005; 128:1717-1751. For small-intestinal carcinoids,which are the most frequent cause of carcinoid syndrome due tometastatic disease in the liver, the incidence of metastasis increasesproportionally with the size of the primary tumor (Tomassetti et al2001, ibidem).

The incidence and survival data available suggest that clinical trialsof new anticancer agents in patients with midgut carcinoid tumors mayprovide the opportunity to address an unmet medical need in a growingsegment of the population of patients with carcinoids.

Carcinoid syndrome is caused by hypersecretion of numerous hormoneproducts by the tumor cells, including kinins, prostaglandins, substanceP, gastrin, corticotrophin and chromogranin A (see e.g. Davis et al,Gynecology & Obstetrics 1973; 137:637-644). Various endocrine orneuroendocrine syndromes can be initial clinical manifestations ofeither typical or atypical pulmonary carcinoid tumors. Carcinoidsyndrome, hypercortisolism and Cushing syndrome, inappropriate secretionof ADH, increased pigmentation secondary to excess MSH, and ectopicinsulin production resulting in hypoglycemia are some of theendocrinopathies that can be produced by a pulmonary carcinoid tumor ina patient who is otherwise asymptomatic.

The most common symptoms are hemoptysis, cough, recurrent pulmonaryinfection, fever, chest discomfort and chest pain, unilateral wheezing,and shortness of breath, flushing and diarrhea. Paraneoplastic syndromesare rare and include carcinoid syndrome, Cushing's syndrome, and ectopicgrowth hormone-releasing hormone secretion.

Other less frequent symptoms include cardiac manifestations secondary tofibrosis of the endocardium (Jacobsen M B et al, Eur Heart J 1995;16:263-268) which may result in valvular regurgitation (valvular heartdisease), with varying degrees of heart failure in patients with cardiacmanifestations. Wheezing or asthma-like symptoms, pellagra-like skinlesions with hyperkeratosis, abdominal pain, telangiectasias andparoxysmal hypotension are also seen in a number of patients. Patientswith pulmonary carcinoid often show symptoms like recurrent pneumonia,cough, hemoptysis or chest pain. The majority of pulmonary carcinoidtumors are in the perihilar area. Ectopic secretion of corticotropinfrom pulmonary carcinoid tumors may also account for Cushing's syndrome.Early in the course, symptoms are usually episodic and may be provokedby stress, catecholamines, and ingestion of food or alcohol. Duringacute paroxysms, systolic blood pressure typically falls 20 to 30 mmHg.Endocardial fibrosis can cause valvular heart disease, usually affectingthe proximal side of the tricuspid and pulmonary valves and leading totricuspid insufficiency and secondary right-sided heart failure.

A recent review of chemotherapeutic treatment of carcinoids reports thatthe sensitivity of these tumors to various cytotoxic drugs is low, andcombination does not increase their effectiveness. Based on their reviewof various combination therapies, including dacarbazine/fluorouracil or5-fluorouracil/epirubicin, the authors conclude that that they areunable to recommend a specific chemotherapeutic regimen for patientswith well-differentiated neuroendocrine malignancies of the GI tract(Arnold R, Rinke A et al, Clinical Gastroenterology 2005;19(4):649-656). The apparent refractoriness of such tumors to currentlyavailable therapies points to an unmet medical need for treatment inthis patient population.

As part of the endocrine system that regulates hormones, the pituitarygland controls many of the other glands through secretion. Our “mastergland,” the pituitary makes some hormones, but also acts as anintermediary between the brain and other endocrine glands. Our hormonesand the pituitary gland accomplish many homeostatic and specializedfunctions, like bone growth and uterine contractions.

Neurons carry messages regarding the production of hormones between thepituitary gland and the hypothalamus. Both are located at the base ofthe brain, nestled in a rounded part of bone, carefully protected. Theyare connected by a bunch of neurons called the infundibulum. Together,they work to regulate all the hormones that circulate in thebloodstream, controlling things like growth and hair pigmentation.Hormones are the long-distance messangers that can inform cells when tobecome active or stay dormant. The pituitary gland controls the thyroid,adrenal glands, ovaries and testes, even though it's only the size of apea.

There are different parts of the pituitary gland that have selectivefunctions. The posterior lobe, called the neurohypophysis, releases thehormones vasopressin and oxytocin, but doesn't produce them. Vasopressinis an anti-diuretic that controls how the kidneys absorb water. Oxytocinis a special hormone only present during childbirth to speedcontractions. The anterior lobe of the pituitary gland is called theadenohypophysis. It produces a variety of hormones, such as prolactinthat stimulates lactation in women. Melanocyte spurs the body to producemelanin for skin and hair pigmentation. Follicle-stimulating hormoneindicates where and when hair should grow during development. The veryimportant growth hormone controls bone growth to determine height,especially active during adolescence. Hormones control glands as well.The thyroid reacts to thyrotropin, the adrenal glands are stimulated byadrenocorticotropin, and the sex glands are affected by luteinizinghormone. The pituitary gland is responsible for many stages and aspectsof our maturation. Pituitary tumors are in general noncancerous(benign), comprising only 10 percent of brain tumors. However, becauseof the location of the pituitary gland, at the base of the skull, apituitary tumor grows upward. And, eventually, many pituitary tumorspress against the optic nerves, causing vision problems. Symptoms varydepending upon what type of tumor is growing and what area of thepituitary gland is affected. Pituitary tumors can cause symptoms thatare caused by excess production of pituitary hormones and symptomscaused by reduced production of pituitary hormones. Other symptoms maybe due to the proximity of these tumors to local brain structures, suchas the optic nerves leading to loss of vision. Each individual alsoexperiences symptoms differently, and the symptoms many resemble otherconditions or medical problems

The most common type of pituitary tumor is called a clinicallynonfunctioning tumor, because patients do not have the classic pituitarysyndromes from excess hormones, such as in acromegaly. These types oftumors may be detected during an evaluation of an incidental problem. Aclinically nonfunctioning tumor may cause hypopituitarism, or anunderactive pituitary gland, which may lead to failure of sexualfunction, reduced sperm production, and cessation of a woman's menstrualperiod, along with fatigue.

Another common pituitary tumor is called a prolactinoma, a benign tumorthat produces the prolactin hormone. Prolactin stimulates breast milkproduction after childbirth. Women with a prolactinoma may have reducedor absent menstrual cycles along with breast milk production.

An uncommon pituitary tumor causes excess growth hormone production (ahormone necessary for normal childhood growth) resulting in acromegaly.In adults, such tumors lead to excessive somatic growth and multiplesystemic, medical consequences. Another uncommon pituitary tumor resultsin Cushing's disease, a disorder of excess steroid production.

Multiple endocrine neoplasia type 1 (MEN 1) is a relatively uncommoninherited disease. Individuals who inherit the gene for MEN 1 have anincreased chance of developing overactivity and enlargement of certainendocrine glands. The endocrine glands most commonly affected by MEN 1are the parathyroid, pancreas, and pituitary glands. Almost everyone whoinherits MEN 1 develops overactivity of the parathyroid glands(hyperparathyroidism) at some stage in their life. The other endocrineglands become overactive less frequently, however, people who inheritMEN 1 will usually develop overactivity in more than one endocrinegland. Overactivity in different endocrine glands may occursimultaneously or at separate times during a persons life. MEN 1 canlead to overactivity and enlargement of the three endocrine glandslisted above (the endocrine glands which start with the letter “P”).People who inherit the gene for MEN 1 are predisposed to developing anoveractivity in hormone production from the parathyroid glands,pituitary gland and pancreas (that is why physicians will measurehormones in the blood to check for overproduction of each specifichormone). Increased hormone production is usually associated withenlargement of these glands, Endocrine gland enlargement and hormoneoverproduction does not usually occur in all areas of an endocrine glandat the same point in time. Some parts of overactive endocrine glandsgrow more rapidly than others, and produce more hormone than other partsof the same gland. The parts of an endocrine gland which grow mostrapidly become “lumpy”. These lumps are usually benign. Benign lumps inendocrine glands are known as adenomas.

Adenomas are benign (not cancerous), and do not spread to other parts ofthe body. Pituitary adenomas (pituitary tumors, nervous system tumor)can lead to nerve damage, growth disturbances, and changes in hormonalbalance. Symptoms of pituitary adenomas can vary considerably, largelydepending on whether or not the tumor is secreting one or more of avariety of hormones. Even if the tumor is not producing any hormones,its location at the base of the brain can cause significant symptoms.Symptoms may e.g. include double or blurred vision, loss of peripheralvision, sudden blindness, headache, dizziness, loss of consciousness,nausea, weakness, unexplained weight changes, amenorrhea, erectiledysfunction in men, decreased sexual desire, especially in men, growthof skull, hands, and feet, deepening of voice, changes in facialappearance (due to changes in facial bones), wider spacing of teeth,joint pain, increased sweating, purple stretch marks on the abdomen,increased hair growth, fat deposits where the neck meets the spine,moodiness or depression, easy bruising, palpitations (rapid or irregularheartbeat), tremor, increased appetite, feeling warm or hot, difficultyfalling asleep, anxiousness, frequent bowel movements, lump in the frontof the neck (enlarged thyroid).

It was found that mTOR inhibitors may be used for the treatment of suchspecial type of tumors

In accordance with the particular findings the present inventionprovides in several aspects:

-   1.1 A method for treating endocrine tumors, comprising administering    to a subject in need thereof a therapeutically effective amount of    an mTOR inhibitor.-   1.2 A method for inhibiting growth of endocrine tumors, comprising    administering to a subject in need thereof a therapeutical effective    amount of an mTOR inhibitor.-   1.3 A method for inhibiting or controlling endocrine tumors,    comprising administering to a subject in need thereof a    therapeutically effective amount of an mTOR inhibitor.-   1.4 A method for inducing endocrine tumor regression, e. g. tumor    mass reduction, comprising administering to a subject in need    thereof a therapeutical effective amount of an mTOR inhibitor.-   1.5 A method for treating endocrine tumor invasiveness or symptoms    associated with such tumor growth, comprising administering to a    subject in need thereof a therapeutically effective amount of an    mTOR inhibitor.-   1.6 A method for preventing metastatic spread of endocrine tumors or    for preventing or inhibiting growth of micrometastasis, comprising    administering to a subject in need thereof a therapeutically    effective amount of an mTOR inhibitor.-   1.7 A method for the treatment of a disorder associated with    endocrine tumors, comprising administering to a subject in need    thereof a therapeutically effective amount of an mTOR inhibitor.-   1.8 The use of an mTOR inhibitor for the manufacture of a medicament    for use in any method of 1.1 to 1.7 above.-   1.9 A pharmaceutical composition comprising an mTOR inhibitor in    association with at least one pharmaceutically acceptable excipient,    e.g. appropriate carrier and/or diluent, e.g. including fillers,    binders, disintegrants, flow conditioners, lubricants, sugars or    sweeteners, fragrances, preservatives, stabilizers, wetting agents    and/or emulsifiers, solubilizers, salts for regulating osmotic    pressure and/or buffers; for use in any method or use of 1.1 to 1.7    above.

Endocrine tumors as indicated herein e.g. include neuroendocrine tumors,e.g. including carcinoid tumors, pancreatic neuroendocrine tumors andtumors in parathyroid, pancreas, and pituitary glands.

Carcinoid tumors as indicated herein e.g. include typical and atypicalcarcinoids, ranging from low-grade malignant typical to intermediateatypical to high-grade large-cell neuroendocrine carcinoma andsmall-cell lung carcinoma; e.g. including carcinoids arising from the

-   -   foregut e.g., bronchial, pulmonary or gastric carcinoids, e.g.        including primary foregut tumors confined to the thymus, lung,        stomach, and duodenum; e.g. carcinoid tumors of the GI tract,        e.g. located in the colon, stomach or small intestine, e.g.        small-intestinal carcinoids, e.g. including    -   midgut, e.g., small intestine or appendiceal carcinoids, e.g.        located in the distal ileum, cecum, and proximal colon, or    -   hindgut, e.g., rectal carcinoids.

Carcinoid lung tumors as indicated herein e.g. include neuroendocrinecarcinoma, Kulchitsky cell carcinoma (KCC) (Kulchitsky cells,argentaffin cells), bronchial carcinoid tumors, bronchial adenomas, e.g.including bronchial adenomas such as a small cell carcinoma and largecell neuroendocrine tumors, typical carcinoids or atypical carcinoidsassociated with large bronchopulmonary carcinoid tumors or small-cellcarcinomas, pulmonary carcinoids, neuroendocrine lung tumors, large-cellneuroendocrine carcinoma of the lung, (primary) pulmonary neoplasms,bronchopulmonary carcinoid tumors, lung neoplasms, lung cancers,pulmonary cancers, intrabronchial mass.

Pancreatic neuroendocrine tumors as indicated herein e.g. include isletcell tumors, APUDomas, insulinomas, glucagonomas, nonfunctioningpancreatic NETs, pancreatic NETs associated with hypercalcemia,gastrinomas, ViPomas, somatostatinomas, GRFomas.

Endocrine or neuroendocrine tumor symptoms as indicated herein e.g.include hemoptysis, cough, recurrent pulmonary infection, fever, chestdiscomfort and chest pain, unilateral wheezing, shortness of breath,flushing and diarrhea, endocrine or neuroendocrine syndromes carcinoidsyndrome, e.g. including manifestations of either typical or atypicalpulmonary carcinoid tumors, Cushing's syndrome, inappropriate secretionof ADH, increased pigmentation secondary to excess MSH, and ectopicinsulin production resulting in hypoglycemia, ectopic growthhormone-releasing hormone secretion, ectopic secretion of corticotropin,cardiac manifestations secondary to fibrosis of the endocardium(endocardial fibrosis), valvular regurgitation (valvular heart disease),tricuspid insufficiency, secondary right-sided heart failure, wheezingor asthma-like symptoms, pellagra-like skin lesions with hyperkeratosis,abdominal pain, telangiectasias and paroxysmal hypotension, recurrentpneumonia, cough, chest pain.

Tumors in parathyroid, pancreas and pituitary glands as indicatedherein, e.g. include pituitary tumors, nervous system tumor, such asadenomas, multiple endocrine neoplasia type 1 (MEN 1).

Pituitary tumor symptoms as indicated herein include symptoms that areassociated with excess production of pituitary hormones and symptomscaused by reduced production of pituitary hormones, loss of vision,clinically nonfunctioning tumor, e.g. associated with hypopituitarismunderactive pituitary gland, e.g. associated with failure of sexualfunction, reduced sperm production, and cessation of a woman's menstrualperiod, along with fatigue, prolactinoma, a benign tumor that producesthe prolactin hormone, acromegaly, e.g. associated with excessivesomatic growth and multiple systemic, medical consequences, Cushing'sdisease, nerve damage, growth disturbances, changes in hormonal balance,double or blurred vision, loss of peripheral vision, sudden blindness,headache, dizziness, loss of consciousness, nausea, weakness,unexplained weight changes, amenorrhea, erectile dysfunction in men,decreased sexual desire, especially in men, growth of skull, hands, andfeet, deepening of voice, changes in facial appearance (due to changesin facial bones), wider spacing of teeth, joint pain, increasedsweating, purple stretch marks on the abdomen, increased hair growth,fat deposits where the neck meets the spine, moodiness or depression,easy bruising, palpitations (rapid or irregular heartbeat), tremor,increased appetite, feeling warm or hot, difficulty falling asleep,anxiousness, frequent bowel movements, lump in the front of the neck(enlarged thyroid).

Where hereinbefore and subsequently a tumor, a tumor disease, acarcinoma or a cancer is mentioned, also metastasis in the originalorgan or tissue and/or in any other location are implied alternativelyor in addition, whatever the location of the tumor and/or metastasis is.

Disorders associated with endocrine tumors include endocrine orneuroendocrine tumor symptoms and pituitary tumor symptoms, such asindicated above.

Disorders include diseases.

An mTOR inhibitor may be used, e.g. in any method of 1.1 to 1.8 asdescribed herein alone or in combination with one or more, at least one,second drug substance.

In other aspects the present invention provides

-   2.1 A combination of an mTOR inhibitor with at least one second drug    substance, e.g. for any use as indicated under 1.1 to 1.8 above.-   2.2 A pharmaceutical combination comprising an mTOR inhibitor in    combination with at least one second drug substance, e.g. for any    use as indicated under 1.1 to 1.8 above.-   2.3 A pharmaceutical composition comprising an mTOR inhibitor in    combination with at least one second drug substance and one or more    pharmaceutically acceptable excipient(s), e.g. for any use as    indicated under 1.1 to 1.8 above.-   2.4 The use of an mTOR inhibitor for the manufacture of a medicament    for use in combination with a second drug substance, e.g. for any    use as indicated under 1.1 to 1.8 above.-   2.5 Any method of 1.1 to 1.8 above comprising co-administering,    concomitantly or in sequence, a therapeutically effective amount of    an mTOR inhibitor and at least one second drug substance, e.g. in    the form of a pharmaceutical combination or composition.-   2.6 An mTOR inhibitor in combination with at least one second drug    substance for use in the preparation of a medicament, e.g. for use    in any method of 1.1 to 1.8 above.-   2.7 Any method as indicated under 2.1 to 2.6 above, wherein the mTOR    inhibitor is administered intermittently.

Combinations include fixed combinations, in which an mTOR inhibitor andat least one second drug substance are in the same formulation; kits, inwhich an mTOR inhibitor and at least one second drug substance inseparate formulations are provided in the same package, e.g. withinstruction for co-administration; and free combinations in which anmTOR inhibitor and at least one second drug substance are packagedseparately, but instruction for concomitant or sequential administrationare given.

In another aspect the present invention provides

-   2.8 A pharmaceutical package comprising a first drug substance which    is an rriTOR inhibitor and at least one second drug substance,    beside instructions for combined administration;-   2.9 A pharmaceutical package comprising an mTOR inhibitor beside    instructions for combined administration with at feast one second    drug substance;-   2.10 A pharmaceutical package comprising at least one second drug    substance beside instructions for combined administration with an    mTOR inhibitor;    e.g. for use in any method of 1.1 to 1.8 above.

Treatment with combinations according to the present invention mayprovide improvements compared with single treatment.

In another aspect the present invention provides

-   2.11 A pharmaceutical combination comprising an amount of an mTOR    inhibitor and an amount of a second drug substance, wherein the    amounts are appropriate to produce a synergistic therapeutic effect.-   2.12—A method for improving the therapeutic utility of a an mTOR    inhibitor comprising co-administering, e.g. concomitantly or in    sequence, a therapeutically effective amount of an mTOR inhibitor    and a second drug substance.-   2.13 A method for improving the therapeutic utility of a second drug    substance comprising co-administering, e.g. concomitantly or in    sequence, a therapeutically effective amount of an mTOR inhibitor    and a second drug substance.    e.g. for use in any method of 1.1 to 1.8 above.

In a method of 2.11 to 2.13 above the activity of an mTOR inhibitor or asecond drug substance may be enhanced compared with single treatment,e.g. combined treatment may result in synergistic effects or mayovercome resistance against an mTOR inhibitor or a chemotherapeuticagent, e.g. when used in any method according to 1.1 to 1.8 as describedabove.

A (pharmaceutical) combination, e.g. composition as indicated under 2.1to 2.13 comprises

-   a) a first agent which is an mTOR inhibitor and-   b) a second drug substance as a co-agent which is a chemotherapeutic    agent, e. g. as defined hereinafter or hereinbefore.

Treatment of disorders (diseases) according to the present inventionincludes prophylaxis (prevention).

For such treatment, the appropriate dosage will, of course, varydepending upon, for example, the chemical nature and the pharmacokineticdata of a compound used, the individual host, the mode of administrationand the nature and severity of the conditions being treated. However, ingeneral, for satisfactory results in larger mammals, for example humans,an indicated daily dosage includes a range

-   -   from about 0.0001 g to about 1.5 g, such as 0.001 g to 1.5 g;    -   from about 0.001 mg/kg body weight to about 20 mg/kg body        weight, such as 0.01 mg/kg body weight to 20 mg/kg body weight,        for example administered in divided doses up to four times a        day.

In a method, for use or in a combination, pharmaceutical combination orpharmaceutical composition provided by the present invention an mTORinhibitor, such as rapamycin or rapamycin derivative, may beadministered as appropriate, e.g. in dosages which are known for mTORinhibitors, by any administration route, e.g. enterally, e.g. orally, orparenterally. E.g. everolimus may be administered, e.g. orally, indosages from 0.1 mg up to 15 mg, such as 0.1 mg to 10 mg. e.g. 0.1 mg,0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 2.5 mg, 5 mg, or 10 mg, more preferablyfrom 0.5 mg to 10 mg, e.g. in the form of (dispersible) tablets; e.g.comprising everolimus in the form of a solid dispersion; e.g. a weeklydosage may include up to 70 mg, e.g. 10 to 70, such as 30 to 50 mg,depending on the disease being treated. Rapamycin or e.g. temsirolimusmay be administered parenterally in similar dosage ranges.

A second drug substance may be administered in combination therapy asappropriate, e.g. according to a method as conventional, e.g.analogously to administration indications given for a specified drug forsingle treatment.

A second drug substance according to the present invention may beadministered by any conventional route, for example enterally, e.g.including nasal, buccal, rectal, oral, administration; parenterally,e.g. including intravenous, intraarterial, intramuscular, intracardiac,subcutanous, intraosseous infusion, transdermal (diffusion through theintact skin), transmucosal (diffusion through a mucous membrane),inhalational administration; topically; e.g. including epicutaneous,intranasal, intratracheal administration; intraperitoneal (infusion orinjection into the peritoneal cavity); epidural (peridural) (injectionor infusion into the epidural space); intrathecal (injection or infusioninto the cerebrospinal fluid); intravitreal (administration via theeye); or via medical devices, e.g. for local delivery, e.g. stents; e.g.in form of coated or uncoated tablets, capsules, (injectable) solutions,infusion solutions, solid solutions, suspensions, dispersions, soliddispersions; e.g. in the form of ampoules, vials, in the form of creams,gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops,sprays, or in the form of suppositories.

A second drug substance according to the present invention may beadministered in the form of a pharmaceutically acceptable salt, or infree form; optionally in the form of a solvate. Pharmaceuticalcompositions according to the present invention may be manufacturedaccording, e.g. analogously, to a method as conventional, e.g. bymixing, granulating, coating, dissolving or lyophilizing processes. Unitdosage forms may contain, for example, from about 0.1 mg to about 1500mg, such as 1 mg to about 1000 mg.

Pharmaceutical compositions comprising a combination of the presentinvention and pharmaceutical compositions comprising a second drugsubstance as described herein, may be provided as appropriate, e.g.according, e.g. analogously, to a method as conventional, or asdescribed herein for a pharmaceutical composition of the presentinvention.

By the term “second drug substance” as used herein is meant either anmTOR inhibitor other than the first drug substance or a chemotherapeuticagent other than an mTOR inhibitor, preferably any chemotherapeuticagent other an mTOR inhibitor.

For example, a second drug substance as used herein includes e.g.

-   -   an anticancer drug, preferably an anti-endocrine tumor agent,    -   an anti-inflammatory and/or immunomodulatory and/or antiallergic        drug,    -   a combination of an anticancer drug with an anti-inflammatory        and/or immunomodulatory drug and/or antiallergic drug.

A second drug substance also include agents which are useful in thetreatment of symptoms associated with carciniod tumors, such ascarcinoid associated diarrhea (e.g. cyproheptadine), carcinoidassociated wheezing (e.g. bronchodilators), carcinoid associated heartfailure (e.g. diuretics, serotonine inhibitors).

In another aspect the present invention provides

-   3. Any method, combination, pharmaceutical combination,    pharmaceutical composition or use as indicated under 1.1 to 1.9 and    2.1 to 2.13 above wherein an mTOR inhibitor is selected from    rapamycin or a rapamycin derivative, such as    -   rapamycin, and/or-   40-O-(2-hydroxyethyl)-rapamycin (also known as everolimus), and/or-   32-deoxorapamycin, and/or-   16-pent-2-ynyloxy-32-deoxorapamycin, and/or-   16-pent-2-ynyloxy-32 (S or R)-dihydro-rapamycin, and/or-   16-pent-2-ynyloxy-32 (S or    R)-dihydro-40-0-(2-hydroxyethyl)-rapamycin, and/or-   40-[3-hydroxy-2-(hydroxy-methyl)-2-methylpropanoate]-rapamycin (also    known as CCI779) and/or-   40-epi-(tetrazolyl)-rapamycin (also known as ABT578), and/or-   the so-called rapalogs, e. g. as disclosed in WO9802441, WO0114387    and WO0384383, AP23573, AP23464, AP23675 or AP23841, e.g. AP23573,    and/or-   compounds disclosed under the name TAFA-93, and/or-   compounds disclosed under the name biolimus;-   e.g. 40-O-(2-hydroxyethyl)-rapamycin (herein also designated as    “compound A”).

In a preferred aspect the present invention provides any method,combination, pharmaceutical combination, pharmaceutical composition, oruse as indicated under 1.1 to 1.9 and 2.1 to 2.13 above for treatingneuroendocrine tumors.

In another preferred aspect the present invention provides any method,combination, pharmaceutical combination, pharmaceutical composition, oruse as indicated under 1.1 to 1.9 and 2.1 to 2.13 above for treatingcarcinoid tumors.

In another preferred aspect the present invention any method,combination, pharmaceutical combination, pharmaceutical composition, oruse as indicated under 1.1 to 1.9 and 2.1 to 2.13 above for treatingpituitary tumors.

Anticancer drugs which are prone to be useful as a combination partnerwith an mTOR inhibitor, e.g. prone to be useful according to the presentinvention, e.g. include

-   i. a steroid; e.g. prednisone.-   ii. an adenosine-kinase-inhibitor; which targets, decreases or    inhibits nucleobase, nucleoside, nucleotide and nucleic acid    metabolisms, such as 5-lodotubercidin, which is also known as    7H-pyrrolo[2,3-d]pyrimidin-4-amine,    5-iodo-7-β-D-ribofuranosyl-(9Cl).-   iii. an adjuvant; which enhances the 5-FU-TS bond as well as a    compound which targets, decreases or inhibits, alkaline phosphatase,    such as leucovorin, levamisole.-   iv. an adrenal cortex antagonist; which targets, decreases or    inhibits the activity of the adrenal cortex and changes the    peripheral metabolism of corticosteroids, resulting in a decrease in    17-hydroxycorticosteroids, such as mitotane,-   v. an AKT pathway inhibitor; such as a compound which targets,    decreases or inhibits Akt, also known as protein kinase B (PKB),    such as deguelin, which is also known as    3H-bis[1]benzopyrano[3,4-b:6′,5′-e]pyran-7(7aH)-one,    13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-(9Cl); and    triciribine, which is also known as    1,4,5,6,8-pentaazaacenaphthylen-3-amine,    1,5-dihydro-5-methyl-1-β-D-ribofuranosyl-(9Cl).-   vi. an alkylating agent; which causes alkylation of DNA and results    in breaks in the DNA molecules as well as cross-linking of the twin    strands, thus interfering with DNA replication and transcription of    RNA, such as chlorambucil, cyclophosphamide, dacarbazine, lomustine,    procarbazine, e.g. in the form of a hydrochloride, thiotepa,    melphalan, temozolomide (TEMODAR®), carmustine, ifosfamide,    mitomycin, altretamine, busulfan, machlorethamine hydrochloride,    nitrosourea (BCNU or Gliadel), streptozocin, estramustine.    Cyclophosphamide can be administered, e.g., in the form as it is    marketed, e.g., under the trademark CYCLOSTIN®; and ifosfamide as    HOLOXAN®.-   vii. an angiogenesis inhibitor; which targets, decreases or inhibits    the production of new blood vessels, e.g. which targets methionine    aminopeptidase-2 (MetAP-2), macrophage inflammatory protein-1    (MIP-1alpha), CCL5, TGF-beta, lipoxygenase, cyclooxygenase, and    topoisomerase, or which indirectly targets p21, p53, CDK2 and    collagen synthesis, e.g. including fumagillin, which is known as    2,4,6,8-decatetraenedioic acid,    mono[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl]    ester, (2E,4E,6E,8E)-(9Cl); shikonin, which is also known as    1,4-naphthalenedione,    5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-(9Cl);    tranilast, which is also known as benzoic acid,    2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-(9Cl); ursolic    acid; suramin; bengamide or a derivative thereof, thalidomide,    TNP-470.-   viii. an anti-androgen; which blocks the action of androgens of    adrenal and testicular origin which stimulate the growth of normal    and malignant prostatic tissue, such as nilutamide; bicalutamide    (CASODEX®), which can be formulated, e.g., as disclosed in U.S. Pat.    No. 4,636,505.-   ix. an anti-estrogen; which antagonizes the effect of estrogens at    the estrogen receptor level, e.g. including an aromatase inhibitor,    which inhibits the estrogen production, i. e. the conversion of the    substrates androstenedione and testosterone to estrone and    estradiol, respectively,    -   e.g. including atamestane, exemestane, formestane,        aminoglutethimide, roglethimide, pyridoglutethimide, trilostane,        testolactone, ketokonazole, vorozole, fadrozole, anastrozole,        letrozole, toremifene; bicalutamide; flutamide; tamoxifen,        tamoxifen citrate; tamoxifen; fulvestrant; raloxifene,        raloxifene hydrochloride. Tamoxifen may be e.g. administered in        the form as it is marketed, e.g., NOLVADEX®; and raloxifene        hydrochloride is marketed as EVISTA®. Fulvestrant may be        formulated as disclosed in U.S. Pat. No. 4,659,516 and is        marketed as FASLODEX®.-   x. an anti-hypercalcemia agent; which is used to treat    hypercalcemia, such as gallium (III) nitrate hydrate; and    pamidronate disodium.-   xi. an antimetabolite; which inhibits or disrupts the synthesis of    DNA resulting in cell death, such as 6-mercaptopurine; cytarabine;    fludarabine; floxuridine; fluorouracil; 5-fluorouracil(5-FU),    floxuridine (5-FUdR), capecitabine; raltitrexed; methotrexate;    cladribine; gemcitabine; gemcitabine hydrochloride; thioguanine;    6-thioguanine, hydroxyurea; DNA de-methylating agents, such as    5-azacytidine and decitabine; edatrexate; folic acid antagonists    such as pemetrexed. Capecitabine and gemcitabine can be administered    e.g. in the marketed form, such as XELODA® and GEMZAR®.-   xii. an apoptosis inducer; which induces the normal series of events    in a cell that leads to its death, e.g. selectively inducing the    X-linked mammalian inhibitor of apoptosis protein XIAP, or e.g.    downregulating BCL-xL; such as ethanol,    2-[[3-(2,3-dichlorophenoxy)propyl]amino]-(9Cl); gambogic acid;    embelin, which is also known as 2,5-cyclohexadiene-1,4-dione,    2,5-dihydroxy-3-undecyl-(9Cl); arsenic trioxide.-   xiii. an aurora kinase inhibitor; which targets, decreases or    inhibits later stages of the cell cycle from the G2/M check point    all the way through to the mitotic checkpoint and late mitosis; such    as binucleine 2, which is also known as methanimidamide,    N′-[1-(3-chloro-4-fluorophenyl)-4-cyano-1H-pyrazol-5-yl]-N,N-dimethyl-(9Cl).-   xiv. a Bruton's Tyrosine Kinase (BTK) inhibitor; which targets,    decreases or inhibits human and murine B cell development; such as    terreic acid.-   xv. a calcineurin inhibitor; which targets, decreases or inhibits    the T cell activation pathway, such as cypermethrin, which is also    known as cyclopropanecarboxylic acid,    3-(2,2-dichloroethenyl)-2,2-dimethykcyano(3-phenoxyphenyl)methyl    ester (9Cl); deltamethrin, which is also known as    cyclopropanecarboxylic aci,    3-(2,2-dibromoethenyl)-2,2-dimethyl-(S)-cyano(3-phenoxyphenyl)methyl    ester, (1R,3R)-(9Cl); fenvalerate, which is also known as    benzeneacetic acid,    4-chloro-α-(1-methylethyl)-,cyano(3-phenoxyphenyl)methyl ester    (9Cl); and Tyrphostin 8; but excluding cyclosporin or FK506.-   xvi. a CaM kinase II inhibitor; which targets, decreases or inhibits    CaM kinases; constituting a family of structurally related enzymes    that include phosphorylase kinase, myosin light chain kinase, and    CaM kinases I-IV; such as 5-isoquinolinesulfonic acid,    4-[(2S)-2-[(5-isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1-piperazinyl)propyl]phenyl    ester (9Cl); benzenesulfonamide,    N-[2-[[[3-(4-chlorophenyl)-2-propenyl]methyl]amino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxy-(9Cl).-   xvii. a CD45 tyrosine phosphatase inhibitor; which targets,    decreases or inhibits dephosphorylating regulatory pTyr residues on    Src-family protein-tyrosine kinases, which aids in the treatment of    a variety of inflammatory and immune disorders; such as phosphonic    acid, [[2-(4-bromophenoxy)-5-nitrophenyl]hydroxymethyl]-(9Cl).-   xviii. a CDC25 phosphatase inhibitor; which targets, decreases or    inhibits overexpressed dephosphorylate cyclin-dependent kinases in    tumors; such as 1,4-naphthalenedione,    2,3-bis[(2-hydroyethyl)thio]-(9Cl).-   xix. a CHK kinase inhibitor; which targets, decreases or inhibits    overexpression of the antiapoptotic protein Bcl-2; such as    debromohymenialdisine. Targets of a CHK kinase inhibitor are CHK1    and/or CHK2.-   xx. a controlling agent for regulating genistein, olomucine and/or    tyrphostins; such as daidzein, which is also known as    4H-1-benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-(9Cl);    Iso-Olomoucine, and Tyrphostin 1.-   xxi. a cyclooxygenase inhibitor; e.g. including Cox-2 inhibitors;    which targets, decreases or inhibits the enzyme cox-2    (cyclooxygenase-2); such as 1H-indole-3-acetamide,    1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-(2-phenylethyl)-(9Cl);    5-alkyl substituted 2-arylaminophenylacetic acid and derivatives,    e.g. celecoxib (CELEBREX®), rofecoxib (VIOXX®), etoricoxib,    valdecoxib; or a 5-alkyl-2-arylaminophenylacetic acid, e.g.,    5-methyl-2-(2′-chloro-6′-fluoroanilino)phenyl acetic acid,    lumiracoxib; and celecoxib.-   xxii. a cRAF kinase inhibitor; which targets, decreases or inhibits    the up-regulation of E-selectin and vascular adhesion molecule-1    induced by TNF; such as    3-(3,5-dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one;    and benzamide,    3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-(9Cl).    Raf kinases play an important role as extracellular    signal-regulating kinases in cell differentiation, proliferation,    and apoptosis. A target of a cRAF kinase inhibitor includes, but is    not limited, to RAF1.-   xxiii. a cyclin dependent kinase inhibitor; which targets, decreases    or inhibits cyclin dependent kinase playing a role in the regulation    of the mammalian cell cycle; such as N9-isopropyl-olomoucine;    olomoucine; purvalanol B, which is also known as Benzoic acid,    2-chloro-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]-(9Cl);    roascovitine; indirubin, which is also known as 2H-indol-2-one,    3-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-(9Cl);    kenpaullone, which is also known as    indolo[3,2-d][1]benzazepin-6(5H)-one, 9-bromo-7,12-dihydro-(9Cl);    purvalanol A, which is also known as 1-Butanol,    2-[[6-[(3-chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-,    (2R)-(9Cl); indirubin-3′-monooxime. Cell cycle progression is    regulated by a series of sequential events that include the    activation and subsequent inactivation of cyclin dependent kinases    (Cdks) and cyclins. Cdks are a group of serine/threonine kinases    that form active heterodimeric complexes by binding to their    regulatory subunits, cyclins. Examples of targets of a cyclin    dependent kinase inhibitor include, but are not limited to, CDK,    AHR, CDK1, CDK2, CDK5, CDK4/6, GSK3beta, and ERK.-   xxiv. a cysteine protease inhibitor; which targets, decreases or    inhibits cystein protease which plays a vital role in mammalian    cellular turnover and apotosis; such as    4-morpholinecarboxamide,N-[(1S)-3-fluoro-2-oxo-1-(2-phenylethyl)propyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-(9Cl).-   xxv. a DNA intercalator; which binds to DNA and inhibits DNA, RNA,    and protein synthesis; such as plicamycin, dactinomycin.-   xxvi. a DNA strand breaker; which causes DNA strand scission and    results in inhibition of DNA synthesis, ininhibition of RNA and    protein synthesis; such as bleomycin.-   xxvii. an E3 Ligase inhibitor; which targets, decreases or inhibits    the E3 ligase which inhibits the transfer of ubiquitin chains to    proteins, marking them for degradation in the proteasome; such as    N-((3,3,3-trifluoro-2-trifluoromethyl)propionyl)sulfanilamide.-   xxviii. an endocrine hormone; which by acting mainly on the    pituitary gland causes the suppression of hormones in males, the net    effect being a reduction of testosterone to castration levels; in    females, both ovarian estrogen and androgen synthesis being    inhibited; such as leuprolide; megestrol, megestrol acetate.-   xxix. compounds targeting, decreasing or inhibiting the activity of    the epidermal growth factor family of receptor tyrosine kinases    (EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers), such as    compounds, proteins or antibodies which inhibit members of the EGF    receptor tyrosine kinase family, e.g. EGF receptor, ErbB2, ErbB3 and    ErbB4 or bind to EGF or EGF-related ligands, and are in particular    those compounds, proteins or monoclonal antibodies generically and    specifically disclosed in WO 9702266, e.g. the compound of ex. 39,    EP0564409, WO9903854, EP0520722, EP0566226, EP0787722, EP0837063,    U.S. Pat. No. 5,747,498, WO9810767, WO9730034, WO9749688, WO9738983    and, especially, WO9630347, e.g. a compound known as CP 358774,    WO9633980, e.g. a compound known as ZD 1839; and WO 9503283, e.g. a    compound known as ZM105180, e.g including trastuzumab (HERCEPTIN®),    cetuximab, iressa, OSI-774, CI-1033, EKB-569, GW-2016, E1.1, E2.4,    E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3,    7H-pyrrolo-[2,3-d]pyrimidine derivatives which are e.g. disclosed in    WO03013541, erlotinib, gefitinib. Erlotinib can be administered in    the form as it is marketed, e.g. TARCEVA®, and gefitinib as IRESSA®,    human monoclonal antibodies against the epidermal growth factor    receptor including ABX-EGFR.-   xxx. an EGFR, PDGFR tyrosine kinase inhibitor; such as EGFR kinase    inhibitors including tyrphostin 23, tyrphostin 25, tyrphostin 47,    tyrphostin 51 and tyrphostin AG 825; 2-propenamide,    2-cyano-3-(3,4-dihydroxyphenyl)-N-phenyl-(2E)-(9Cl); tyrphostin Ag    1478; lavendustin A; 3-pyridineacetonitrile,    α-[(3,5-dichlorophenyl)methylene]-, (αZ)-(9Cl); an example of an    EGFR, PDGFR tyrosine kinase inhibitor e.g. includes tyrphostin 46.    PDGFR tyrosine kinase inhibitor including tyrphostin 46. Targets of    an EGFR kinase inhibitor include guanylyl cyclase (GC-C) HER2, EGFR,    PTK and tubulin.-   xxxi. a farnesyltransferase inhibitor; which targets, decreases or    inhibits the Ras protein; such as a-hydroxyfarnesylphosphonic acid;    butanoic acid,    2-[[(2S)-2-[[(2S,3S)-2-[[(2R)-2-amino-3-mercaptopropyl]amino]-3-methylpentyl]oxyl]1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-,    1-methylethyl ester, (2S)-(9Cl); manumycin A; L-744,832 or DK8G557,    tipifarnib (R115777), SCH66336 (lonafarnib), BMS-214662,-   xxxii. a Flk-1 kinase inhibitor; which targets, decreases or    inhibits Flk-1 tyrosine kinase activity; such as 2-propenamide,    2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-(2E)-(9Cl).    A target of a Flk-1 kinase inhibitor includes, but is not limited    to, KDR.-   xxxiii. a Glycogen synthase kinase-3 (GSK3) inhibitor; which    targets, decreases or inhibits glycogen synthase kinase-3 (GSK3);    such as indirubin-3′-monooxime. Glycogen Synthase Kinase-3 (GSK-3;    tau protein kinase I), a highly conserved, ubiquitously expressed    serine/threonine protein kinase, is involved in the signal    transduction cascades of multiple cellular processes. which is a    protein kinase that has been shown to be involved in the regulation    of a diverse array of cellular functions, including protein    synthesis, cell proliferation, cell differentiation, microtubule    assembly/disassembly, and apoptosis.-   xxxiv. a histone deacetylase (HDAC) inhibitor; which inhibits the    histone deacetylase and which possess anti-proliferative activity;    such as compounds disclosed in WO0222577, especially    N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide,    and    N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide    and pharmaceutically acceptable salts thereof; suberoylanilide    hydroxamic acid (SAHA);    [4-(2-amino-phenylcarbamoyl)-benzyl]-carbamic acid    pyridine-3-ylmethyl ester and derivatives thereof; butyric acid,    pyroxamide, trichostatin A, oxamflatin, apicidin, depsipeptide;    depudecin; trapoxin, HC toxin, which is also known as    cyclo[L-alanyl-D-alanyl-(□S,2S)-□-amino-□-oxooxiraneoctanoyl-D-prolyl](9Cl);    sodium phenylbutyrate, suberoyl bis-hydroxamic acid; Trichostatin A,    BMS-27275, pyroxamide, FR-901228, valproic acid.-   xxxv. a HSP90 inhibitor; which targets, decreases or inhibits the    intrinsic ATPase activity of HSP90; degrades, targets, decreases or    inhibits the HSP90 client proteins via the ubiquitin proteosome    pathway. Compounds targeting, decreasing or inhibiting the intrinsic    ATPase activity of HSP90 are especially compounds, proteins or    antibodies which inhibit the ATPase activity of HSP90, e.g.,    17-allylamino, 17-demethoxygeldanamycin (17AAG), a geldanamycin    derivative; other geldanamycin-related compounds; radicicol and HDAC    inhibitors. Other examples of an HSP90 inhibitor include    geldanamycin, 17-demethoxy-17-(2-propenylamino)-(9Cl). Potential    indirect targets of an HSP90 inhibitor include FLT3, BCR-ABL, CHK1,    CYP3A5*3 and/or NQ01*2.-   xxxvi. a I-kappa B-alpha kinase inhibitor (IKK); which targets,    decreases or inhibits NF-kappaB, such as 2-propenenitrile,    3-[(4-methylphenyl)sulfonyl]-(2E)-(9Cl).-   xxxvii. an insulin receptor tyrosine kinase inhibitor; which    modulates the activities of phosphatidylinositol 3-kinase,    microtubule-associated protein, and S6 kinases; such as    hydroxyl-2-naphthalenylmethylphosphonic acid, LY294002.-   xxxviii. a c-Jun N-terminal kinase (JNK) kinase inhibitor; which    targets, decreases or inhibits Jun N-terminal kinase; such as    pyrazoleanthrone and/or epigallocatechin gallate. Jun N-terminal    kinase (JNK), a serine-directed protein kinase, is involved in the    phosphorylation and activation of c-Jun and ATF2 and plays a    significant role in metabolism, growth, cell differentiation, and    apoptosis. A target for a JNK kinase inhibitor includes, but is not    limited to, DNMT.-   xxxix a microtubule binding agent; which acts by disrupting the    microtubular network that is essential for mitotic and interphase    cellular function; such as vinblastine, vinblastine sulfate; vinca    alkaloids, such as vincristine, vincristine sulfate; vindesine;    vinorelbine; taxanes, such as docetaxel; paclitaxel;    discodermolides; cochicine, epothilones and derivatives thereof,    e.g. epothilone B or a derivative thereof. Paclitaxel is marketed as    TAXOL®; docetaxel as TAXOTERE®; vinblastine sulfate as VINBLASTIN    R.P®; and vincristine sulfate as FARMISTIN®. Also included are the    generic forms of paclitaxel as well as various dosage forms of    paclitaxel. Generic forms of paclitaxel include, but are not limited    to, betaxoloi hydrochloride. Various dosage forms of paclitaxel    include, but are not limited to albumin nanoparticle paclitaxel    marketed as ABRAXANE®; ONXOL®, CYTOTAX®. Discodermolide can be    obtained, e.g., as disclosed in U.S. Pat. No. 5,010,099. Also    included are Epotholine derivatives which are disclosed in U.S. Pat.    No. 6,194,181, WO98/0121, WO9825929, WO9808849, WO9943653, WO9822461    and WO0031247. Especially preferred are Epotholine A and/or B.-   xl. a mitogen-activated protein (MAP) kinase-inhibitor; which    targets, decreases or inhibits Mitogen-activated protein, such as    benzenesulfonamide,    N-[2-[[[3-(4-chlorophenyl)-2-propenyl]methyl]amino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxy-(9Cl).    The mitogen-activated protein (MAP) kinases are a group of protein    serine/threonine kinases that are activated in response to a variety    of extracellular stimuli and mediate signal transduction from the    cell surface to the nucleus. They regulate several physiological and    pathological cellular phenomena, including inflammation, apoptotic    cell death, oncogenic transformation, tumor cell invasion, and    metastasis.-   xli. a MDM2 inhibitor; which targets, decreases or inhibits the    interaction of MDM2 and the p53 tumor suppressor; such as    trans-4-iodo, 4′-boranyl-chalcone.-   xlii. a MEK inhibitor; which targets, decreases or inhibits the    kinase activity of MAP kinase MEK; such as Nexavar® (sorafenib    tosylate), butanedinitrile,    bis[amino[2-aminophenyl)thio]methylene]-(9Cl). A target of a MEK    inhibitor includes, but is not limited to ERK. An indirect target of    a MEK inhibitor includes, but is not limited to, cyclin D1.-   xliii. a matrix metalloproteinase inhibitor (MMP) inhibitor; which    targets, decreases or inhibits a class of protease enzyme that    selectively catalyze the hydrolysis of polypeptide bonds including    the enzymes MMP-2 and MMP-9 that are involved in promoting the loss    of tissue structure around tumors and facilitating tumor growth,    angiogenesis, and metastasis such as actinonin, which is also known    as butanediamide,    N-4-hydroxy-N1-[(1S)-1-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-2-pentyl-,    (2R)-(9Cl); epigallocatechin gallate; collagen peptidomimetic and    non-peptidomimetic inhibitors; tetracycline derivatives, e.g.,    hydroxamate peptidomimetic inhibitor batimastat; and its    orally-bioavailable analogue marimastat, prinomastat, metastat,    neovastat, tanomastat, TAA211, BMS-279251, BAY 12-9566, MM1270B or    AAJ996. A target of a MMP inhibitor includes, but is not limited to,    polypeptide deformylase.-   xliv. a NGFR tyrosine-kinase-inhibitor; which targets, decreases or    inhibits nerve growth factor dependent p140^(c-trk) tyrosine    phosphorylation; such as tyrphostin AG 879. Targets of a NGFR    tyrosine-kinase-inhibitor include, but are not limited to, HER2,    FLK1, FAK, TrkA, and/or TrkC. An indirect target inhibits expression    of RAF1.-   xlv. a p38 MAP kinase inhibitor, including a SAPK2/p38 kinase    inhibitor; which targets, decreases or inhibits p38-MAPK, which is a    MAPK family member, such as phenol,    4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-(9Cl). An    example of a a SAPK2/p38 kinase inhibitor includes, but is not    limited to, benzamide,    3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-(9Cl).    A MAPK family member is a serine/threonine kinase activated by    phosphorylation of tyrosine and threonine residues. This kinase is    phosphorylated and activated by many cellular stresses and    inflammatory stimuli, thought to be involved in the regulation of    important cellular responses such as apoptosis and inflammatory    reactions.-   xlvi. a p56 tyrosine kinase inhibitor; which targets, decreases or    inhibits p56 tyrosine kinase, which is an enzyme that is a    lymphoid-specific src family tyrosine kinase critical for T-cell    development and activation; such as damnacanthal, which is also    known as    2-anthracenecarboxaldehyde,9,10-dihydro-3-hydroxy-1methoxy-9,10-dioxo-(9Cl),    Tyrphostin 46. A target of a p56 tyrosine kinase inhibitor includes,    but is not limited to, Lck. Lck is associated with the cytoplasmic    domains of CD4, CD8 and the beta-chain of the IL-2 receptor, and is    thought to be involved in the earliest steps of TCR-mediated T-cell    activation.-   xlvii. a PDGFR tyrosine kinase inhibitor; targeting, decreasing or    inhibiting the activity of the C-kit receptor tyrosine kinases (part    of the PDGFR family), such as targeting, decreasing or inhibiting    the activity of the c-Kit receptor tyrosine kinase family,    especially inhibiting the c-Kit receptor. Examples of targets of a    PDGFR tyrosine kinase inhibitor includes, but are not limited to    PDGFR, FLT3 and/or c-KIT; such as tyrphostin AG 1296; tyrphostin 9;    1,3-butadiene-1,1,3-tricarbonitrile,2-amino-4-(1H-indol-5-yl)-(9Cl);    N-phenyl-2-pyrimidine-amine derivative, e. g. imatinib, IRESSA®.    PDGF plays a central role in regulating cell proliferation,    chemotaxis, and survival in normal cells as well as in various    disease states such as cancer, atherosclerosis, and fibrotic    disease. The PDGF family is composed of dimeric isoforms (PDGF-AA,    PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD), which exert their cellular    effects by differentially binding to two receptor tyrosine kinases.    PDGFR-α and PDGFR-β have molecular masses of 170 and 180 kDa,    respectively.-   xlviii. a phosphatidylinositol 3-kinase inhibitor; which targets,    decreases or inhibits PI 3-kinase; such as wortmannin, which is also    known as 3H-Furo[4,3,2-de]indeno[4,5-h]-2-benzopyran-3,6,9-trione,    11-(acetyloxy)-1,6b,7,8,9a,10,11,11b-octahydro-1-(methoxymethyl)-9a,11b-dimethyl-,    (1S,6bR,9aS,11R,11bR)-(9Cl);    8-phenyl-2-(morpholin-4-yl)-chromen-4-one; quercetin, quercetin    dihydrate. PI 3-kinase activity has been shown to increase in    response to a number of hormonal and growth factor stimuli,    including insulin, platelet-derived growth factor, insulin-like    growth factor, epidermal growth factor, colony-stimulating factor,    and hepatocyte growth factor, and has been implicated in processes    related to cellular growth and transformation. An example of a    target of a phosphatidylinositol 3-kinase inhibitor includes, but is    not limited to, Pi3K.-   xlix. a phosphatase inhibitor; which targets, decreases or inhibits    phosphatase; such as cantharidic acid; cantharidin; and    L-leucinamide,    N-[4-(2-carboxyethenyl)benzoyl]glycyl-L-α-glutamyl-(E)-(9Cl).    Phosphatases remove the phosphoryl group and restore the protein to    its original dephosphorylated state. Hence, the    phosphorylation-dephosphorylation cycle can be regarded as a    molecular “on-off” switch.-   l. platinum agent; which contains platinum and inhibit DNA synthesis    by forming interstrand and intrastrand cross-linking of DNA    molecules; such as carboplatin; cisplatin; oxaliplatin; cisplatinum;    satraplatin and platinum agents such as ZD0473. Carboplatin can be    administered, e.g., in the form as it is marketed, e.g. CARBOPLAT®;    and oxaliplatin as ELOXATIN®.-   li. a protein phosphatase inhibitor, including a PP1 and PP2    inhibitor and a tyrosine phosphatase inhibitor; which targets,    decreases or inhibits protein phosphatase. Examples of a PP1 and    PP2A inhibitor include cantharidic acid and/or cantharidin. Examples    of a tyrosine phosphatase inhibitor include, but are not limited to,    L-P-bromotetramisole oxalate; 2(5H)-furanone,    4-hydroxy-5-(hydroxymethyl)-3-(1-oxohexadecyl)-, (5R)-(9Cl); and    benzylphosphonic acid.

The term “a PP1 or PP2 inhibitor”, as used herein, relates to a compoundwhich targets, decreases or inhibits Ser/Thr protein phosphatases. TypeI phosphatases, which include PP1, can be inhibited by two heat-stableproteins known as Inhibitor-1 (I-1) and Inhibitor-2 (I-2). Theypreferentially dephosphorylate a subunit of phosphorylase kinase. TypeII phosphatases are subdivided into spontaneously active (PP2A),CA²⁺-dependent (PP2B), and Mg²⁺-dependent (PP2C) classes ofphosphatases.

The term “tyrosine phosphatase inhibitor”, as used here, relates to acompounds which targets, decreases or inhibits tyrosine phosphatase.Protein tyrosine phosphatases (PTPs) are relatively recent additions tothe phosphatase family. They remove phosphate groups from phosphorylatedtyrosine residues of proteins. PTPs display diverse structural featuresand play important roles in the regulation of cell proliferation,differentiation, cell adhesion and motility, and cytoskeletal function.Examples of targets of a tyrosine phosphatase inhibitor include, but arenot limited to, alkaline phosphatase (ALP), heparanase, PTPase, and/orprostatic acid phosphatase.

-   lii. a PKC inhibitor and a PKC delta kinase inhibitor: The term “a    PKC inhibitor”, as used herein, relates to a compound which targets,    decreases or inhibits protein kinase C as well as its isozymes.    Protein kinase C (PKC), a ubiquitous, phospholipid-dependent enzyme,    is involved in signal transduction associated with cell    proliferation, differentiation, and apoptosis. Examples of a target    of a PKC inhibitor include, but are not limited to, MAPK and/or    NF-kappaB. Examples of a PKC inhibitor include, but are not limited    to,    1-H-pyrrolo-2,5-dione,3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-(9Cl);    bisindolylmaleimide IX; sphingosine, which is known as    4-octadecene-1,3-diol, (2S,3R,4E)-(9Cl); staurosporine, which is    known as    9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one,    staurosporine derivatives such as disclosed in EP0296110, e. g.    midostaurin;    2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-,    (9S,10R,11R,13R)-(9Cl); tyrphostin 51; and hypericin, which is also    known as phenanthro[1,10,9,8-opqra]perylene-7,14-dione,    1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer    (6Cl,7Cl,8Cl,9Cl), UCN-01,safingol, BAY 43-9006, bryostatin 1,    perifosine; limofosine; RO 318220 and RO 320432; GO 6976; Isis 3521;    LY333531/LY379196. The term “a PKC delta kinase inhibitor”, as used    herein, relates to a compound which targets, decreases or inhibits    the delta isozymes of PKC. The delta isozyme is a conventional PKC    isozymes and is Ca²⁺-dependent. An example of a PKC delta kinase    inhibitor includes, but is not limited to, Rottlerin, which is also    known as 2-Propen-1-one,    1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-,    (2E)-(9Cl).-   liii. a polyamine synthesis inhibitor; which targets, decreases or    inhibits polyamines spermidine; such as DMFO, which is also known as    (−)-2-difluoromethylomithin; N1, N12-diethylspermine 4HCl. The    polyamines spermidine and spermine are of vital importance for cell    proliferation, although their precise mechanism of action is    unclear. Tumor cells have an altered polyamine homeostasis reflected    by increased activity of biosynthetic enzymes and elevated polyamine    pools.-   liv. a proteosome inhibitor; which targets, decreases or inhibits    proteosome, such as aclacinomycin A; gliotoxin; PS-341; MLN 341;    bortezomib; velcade. Examples of targets of a proteosome inhibitor    include, but are not limited to, O(2)(−)-generating NADPH oxidase,    NF-kappaB, and/or farnesyltransferase, geranyltransferase I.-   lv. a PTP1B inhibitor; which targets, decreases or inhibits PTP1B, a    protein tyrosine kinase inhibitor; such as L-leucinamide,    N-[4-(2-carboxyethenyl)benzoyl]glycyl-L-α-glutamyl-,(E)-(9Cl).-   lvi. a protein tyrosine kinase inhibitor including a SRC family    tyrosine kinase inhibitor; a Syk tyrosine kinase inhibitor; and a    JAK-2 and/or JAK-3 tyrosine kinase inhibitor; The term “a protein    tyrosine kinase inhibitor”, as used herein, relates to a compound    which which targets, decreases or inhibits protein tyrosine kinases.    Protein tyrosine kinases (PTKs) play a key role in the regulation of    cell proliferation, differentiation, metabolism, migration, and    survival. They are classified as receptor PTKs and non-receptor    PTKs. Receptor PTKs contain a single polypeptide chain with a    transmembrane segment. The extracellular end of this segment    contains a high affinity ligand-binding domain, while the    cytoplasmic end comprises the catalytic core and the regulatory    sequences. Examples of targets of a tyrosine kinase inhibitor    include, but are not limited to, ERK1, ERK2, Bruton's tyrosine    kinase (Btk), JAK2, ERK½, PDGFR, and/or FLT3. Examples of indirect    targets include, but are not limited to, TNFalpha, NO, PGE2, IRAK,    iNOS, ICAM-1, and/or E-selectin. Examples of a tyrosine kinase    inhibitor include, but are not limited to, tyrphostin AG 126,    tyrphostin Ag 1288; tyrphostin Ag 1295; geldanamycin; and genistein.    -   Non-receptor tyrosine kinases include members of the Src, Tec,        JAK, Fes, Abl, FAK, Csk, and Syk families. They are located in        the cytoplasm as well as in the nucleus. They exhibit distinct        kinase regulation, substrate phosphorylation, and function.        Deregulation of these kinases has also been linked to several        human diseases. The term “a SRC family tyrosine kinase        inhibitor”, as used herein, relates to a compound which which        targets, decreases or inhibits SRC. Examples of a SRC family        tyrosine kinase inhibitor include, but are not limited to, PP1,        which is also known as 1H-pyrazolo[3,4-d]pyrimidin-4-amine,        1-(1,1-dimethylethyl)-3-(1-naphthalenyl)-(9Cl); and PP2, which        is also known as 1H-Pyrazolo[3,4-d]pyrimidin-4-amine,        3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-(9Cl).

The term “a Syk tyrosine kinase inhibitor”, as used herein, relates to acompound which targets, decreases or inhibits Syk. Examples of targetsfor a Syk tyrosine kinase inhibitor include, but are not limited to,Syk, STAT3, and/or STAT5. An example of a Syk tyrosine kinase inhibitorincludes, but is not limited to, piceatannol, which is also known as1,2-benzenediol, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]-(9Cl).

The term “a Janus (JAK-2 and/or JAK-3) tyrosine kinase inhibitor”, asused herein, relates to a compound which targets, decreases or inhibitsjanus tyrosine kinase. Janus tyrosine kinase inhibitor are shownanti-leukemic agents with anti-thrombotic, anti-allergic andimmunosuppressive properties. Targets of a JAK-2 and/or JAK-3 tyrosinekinase inhibitor include, but are not limited to, JAK2, JAK3, STAT3. Anindirect target of an JAK-2 and/or JAK-3 tyrosine kinase inhibitorincludes, but is not limited to CDK2. Examples of a JAK-2 and/or JAK-3tyrosine kinase inhibitor include, but are not limited to, Tyrphostin AG490; and 2-naphthyl vinyl ketone.

-   -   Compounds which target, decrease or inhibit the activity of        c-Abl family members and their gene fusion products, a g.        include PD180970; AG957; or NSC 680410.

-   lvii. a retinoid; which target, decrease or inhibit retinoid    dependent receptors; such as isotretinoin, tretinoin.

-   lviii. a RNA polymerase II elongation inhibitor; which targets,    decreases or inhibits insulin-stimulated nuclear and cytosolic p70S6    kinase in CHO cells; targets, decreases or inhibits RNA polymerase    II transcription, which may be dependent on casein kinase II; and    targets, decreases or inhibits germinal vesicle breakdown in bovine    oocytes; such as 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.

-   lvix. a serine/threonine kinase inhibitor; which inhibits    serine/threonine kinases; such as 2-aminopurine, also known as    1H-purin-2-amine(9Cl). An example of a target of a serine/threonine    kinase inhibitor includes, but is not limited to, dsRNA-dependent    protein kinase (PKR). Examples of indirect targets of a    serine/threonine kinase inhibitor include, but are not limited to,    MCP-1, NF-kappaB, eIF2alpha, COX2, RANTES, IL8,CYP2A5, IGF-1,    CYP2B1, CYP2B2, CYP2H1, ALAS-1, HIF-1, erythropoietin, and/or    CYP1A1.

-   lx. a sterol biosynthesis inhibitor; which inhibits the biosynthesis    of sterols such as cholesterol; such as terbinadine. Examples of    targets for a sterol biosynthesis inhibitor include, but are not    limited to, squalene epoxidase, and CYP2D6.

-   lxi. a topoisomerase inhibitor; including a topoisomerase I    inhibitor and a topoisomerase II inhibitor. Examples of a    topoisomerase I inhibitor include, but are not limited to,    topotecan, gimatecan, irinotecan, camptothecan and its analogues,    9-nitrocamptothecin and the macromolecular camptothecin conjugate    PNU-166148 (compound A1 in WO9917804); 10-hydroxycamptothecin    acetate salt; etoposide; idarubicin hydrochloride; irinotecan    hydrochloride; teniposide; topotecan, topotecan hydrochloride;    doxorubicin; epirubicin, epirubicin hydrochloride; mitoxantrone,    mitoxantrone hydrochloride; daunorubicin, daunorubicin    hydrochloride, dasatinib (BMS-354825). Irinotecan can be    administered, e.g., in the form as it is marketed, e.g., under the    trademark CAMPTOSAR®. Topotecan can be administered, e.g., in the    form as it is marketed, e.g., under the trademark HYCAMTIN®. The    term “topoisomerase II inhibitor”, as used herein, includes, but is    not limited to, the anthracyclines, such as doxorubicin, including    liposomal formulation, e.g., CAELYX®, daunorubicin, including    liposomal formulation, e.g., DAUNOSOME®, epirubicin, idarubicin and    nemorubicin; the anthraquinones mitoxantrone and losoxantrone; and    the podophillotoxines etoposide and teniposide. Etoposide is    marketed as ETOPOPHOS®; teniposide as VM 26-BRISTOL®; doxorubicin as    ADRIBLASTIN® or ADRIAMYCIN®; epirubicin as FARMORUBICIN® idarubicin    as ZAVEDOS®; and mitoxantrone as NOVANTRON®.

-   lxii. VEGFR tyrosine kinase inhibitor; which targets, decreases    and/or inhibits the known angiogenic growth factors and cytokines    implicated in the modulation of normal and pathological    angiogenesis. The VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF-D) and    their corresponding receptor tyrosine kinases [VEGFR-1 (Flt-1),    VEGFR-2 (Flk-1, KDR), and VEGFR-3 (Flt-4)] play a paramount and    indispensable role in regulating the multiple facets of the    angiogenic and lymphangiogenic processes. An example of a VEGFR    tyrosine kinase inhibitor includes    3-(4-dimethylaminobenzylidenyl)-2-indolinone. Compounds which    target, decrease or inhibit the activity of VEGFR are especially    compounds, proteins or antibodies which inhibit the VEGF receptor    tyrosine kinase, inhibit a VEGF receptor or bind to VEGF, and are in    particular those compounds, proteins or monoclonal antibodies    generically and specifically disclosed in WO9835958, e. g.    1-(4-chloroanilino)-4-(4-pyridylmethyl) phthalazine or a    pharmaceutical acceptable salt thereof, e. g. the succinate, or in    WO0009495, WO0027820, WO0059509, WO9811223, WO0027819 and EP0769947;    e.g. those as described by M. Prewett et al in Cancer Research    59 (1999) 5209-5218, by F. Yuan et al in Proc. Nati. Acad. Sci. USA,    vol. 93, pp. 14765-14770, December 1996, by Z. Zhu et al in Cancer    Res. 58,1998, 3209-3214, and by J. Mordenti et al in Toxicologic    Pathology, Vol. 27, no. 1, pp 14-21, 1999; in WO0037502 and    WO9410202; Angiostatin, described by M. S. O'Reilly et al, Cell 79,    1994, 315-328; Endostatin described by M. S. O'Reilly et al, Cell    88, 1997, 277-285; anthranilic acid amides; ZD4190; ZD6474; SU5416;    SU6668; or anti-VEGF antibodies or anti-VEGF receptor    antibodies, e. g. RhuMab (bevacizumab). By antibody is meant intact    monoclonal antibodies, polyclonal antibodies, multispecific    antibodies formed from at least 2 intact antibodies, and antibodies    fragments so long as they exhibit the desired biological activity an    example of an VEGF-R2 inhibitor e.g. includes axitinib,

-   lxiii. a gonadorelin agonist, such as abarelix, goserelin, goserelin    acetate,

-   lxiv. a compound which induce cell differentiation processes, such    as retinoic acid, alpha-, gamma- or 8-tocopherol or alpha-, gamma-    or 8-tocotrienol.

-   lxv. a bisphosphonate, e.g. including etridonic, clodronic,    tiludronic, pamidronic, alendronic, ibandronic, risedronic and    zoledronic acid.

-   lxvi. a heparanase inhibitor which prevents heparan sulphate    degradation, e. g. PI-88,

-   lxvii. a biological response modifier, preferably alymphokine or    interferons, e. g. interferon alpha,

-   lxviii. a telomerase inhibitor, e. g. telomestatin,

-   lxix. mediators, such as inhibitors of catechol-O-methyltransferase,    e.g. entacapone,

-   lxx: ispinesib, permetrexed (Alimta®), sunitinib (SU11248),    diethylstilbestrol (DES), BMS224818 (LEA29Y),

-   lxxi somatostatin or a somatostatin analogue, such as octreotide    (Sandostatin® or Sandostatin LAR®).

-   lxxii. Growth Hormone-Receptor Antagonists, such as pegvisomant,    filgrastim or pegfilgrastim, or interferon alpha.

Cancer treatment, such as endocrine tumor treatment with an mTORinhibitor, optionally in combination with an anticancer drug, such asindicated herein, may be associated with radiotherapy. Edocrine tumortreatment with an mTOR inhibitor, optionally in combination with ananticancer drug, may be a second line treatment, e.g. followingtreatment with another anticancer drug.

A preferred anticancer drug as a second drug substance in endocrinetumor treatment e.g. includes 5-fluorouracil, dacarbazine,streptozotocin, a receptor tyrosine kinase inhibitor that has a spectrumof activity that includes PDGFR, C-kit, and the VEGF receptor, e.g.SU011248, growth Hormone-Receptor Antagonists, such as pegvisomant,filgrastim or pegfilgrastim, interferon alpha or somatostatin or asomatostatin analogue, such as octreotide.

Preferably a second drug substance is somatostatin or a somatostatinanalogue, such as octreotide, sold under the trade name Sandostatin® orSandostatin LAR®.

Anti-inflammatory and/or immunomodulatory drugs which are prone to beuseful in combination with an mTOR inhibitor e.g. prone to be usefulaccording to the present invention, e.g. include

-   -   mediators, e.g. inhibitors, of calcineurin, e.g. cyclosporin A,        FK 506;    -   ascomycins having immuno-suppressive properties, e.g. ABT-281,        ASM981;    -   corticosteroids; cyclophosphamide; azathioprene; leflunomide;        mizoribine;    -   mycophenolic acid or salt; e.g. sodium, mycophenolate mofetil;    -   15-deoxyspergualine or an immunosuppressive homologue, analogue        or derivative thereof;    -   mediators, e.g. inhibitors, of bcr-abl tyrosine kinase activity;    -   mediators, e.g. inhibitors, of c-kit receptor tyrosine kinase        activity;    -   mediators, e.g. inhibitors, of PDGF receptor tyrosine kinase        activity, e.g. Gleevec (imatinib);    -   mediators, e.g. inhibitors, of p38 MAP kinase activity,    -   mediators, e.g. inhibitors, of VEGF receptor tyrosine kinase        activity,    -   mediators, e.g. inhibitors, of PKC activity, e.g. as disclosed        in WO0238561 or WO0382859, e.g. the compound of Example 56 or        70;    -   mediators, e.g. inhibitors, of JAK3 kinase activity, e.g.        N-benzyl-3,4-dihydroxy-benzylidene-cyanoacetamide        α-cyano-(3,4-dihydroxy)-]N-benzylcinnamamide (Tyrphostin AG        490), prodigiosin 25-C (PNU156804),        [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]        (WHI-P131),        [4-(3′-bromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline]        (WHI-P154),        [4-(3′,5-dibromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline]        WHI-P97, KRX-211,        3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile,        in free form or in a pharmaceutically acceptable salt form, e.g.        mono-citrate (also called CP-690,550), or a compound as        disclosed in WO2004052359 or WO2005066156;    -   mediators, e.g. agonists or modulators of S1P receptor activity,        e.g. FTY720 optionally phosphorylated or an analog thereof, e.g.        2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol        optionally phosphorylated or        1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic        acid or its pharmaceutically acceptable salts;    -   immunosuppressive monoclonal antibodies, e.g., monoclonal        antibodies to leukocyte receptors, e.g., Blys/BAFF receptor,        MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, C052,        CD58, CD80, CD86, IL-12 receptor, IL-17 receptor, IL-23 receptor        or their ligands;    -   other immunomodulatory compounds, e.g. a recombinant binding        molecule having at least a portion of the extracellular domain        of CTLA4 or a mutant thereof, e.g. an at least extracellular        portion of CTLA4 or a mutant thereof joined to a non-CTLA4        protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629)        or a mutant thereof, e.g. LEA29Y;    -   mediators, e.g. inhibitors of adhesion molecule activities, e.g.        LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists        or VLA-4 antagonists,    -   mediators, e.g. antagonists of CCR9 activity,    -   mediators, e.g. inhibitors, of MIF activity,    -   5-aminosalicylate (5-ASA) agents, such as sulfasalazine,        Azulfidine®, Asacol®, Dipentum®, Pentasa®, Rowasa®, Canasa®,        Colazal®, e.g. drugs containing mesalamine; e.g mesalazine in        combination with heparin;    -   mediators, e.g. inhibitors, of TNF-alpha activity, e.g.        including antibodies which bind to TNF-alpha, e.g. infliximab        (Remicade®), thalidomide, lenalidomide,    -   nitric oxide releasing non-steriodal anti-inflammatory drugs        (NSAIDs), e.g. including COX-inhibiting NO-donating drugs        (CINOD);    -   phospordiesterase, e.g. mediators, such as inhibitors of PDE4B        activity,    -   mediators, e.g. inhibitors, of caspase activity,    -   mediators, e.g. agonists, of the G protein coupled receptor        GPBAR1,    -   mediators, e.g. inhibitors, of ceramide kinase activity,    -   ‘multi-functional anti-inflammatory’ drugs (MFAIDs), e.g.        cytosolic phoshpholipase A2 (cPLA2) inhibitors, such as        membrane-anchored phospholipase A2 inhibitors linked to        glycosaminoglycans;    -   antibiotics, such as penicillins, cephalosporins, erythromycins,        tetracyclines, sulfonamides, such as sulfadiazine,        sulfisoxazole; sulfones, such as dapsone; pleuromutilins,        fluoroquinolones, e.g. metronidazole, quinolones such as        ciprofloxacin; levofloxacin; probiotics and commensal bacteria        e.g. Lactobacillus, Lactobacillus reuteri;    -   antiviral drugs, such as ribivirin, vidarabine, acyclovir,        ganciclovir, zanamivir, oseltamivir phosphate, famciclovir,        atazanavir, amantadine, didanosine, efavirenz, foscarnet,        indinavir, lamivudine, nelfinavir, ritonavir, saquinavir,        stavudine, valacyclovir, valganciclovir, zidovudine.

Anti-inflammatory drugs which are prone to be useful in combination withan mTOR inhibitor, e.g. prone to be useful according to the presentinvention, include e.g. non-steroidal antiinflammatory agents (NSAIDs)such as propionic acid derivatives (alminoprofen, benoxaprofen, bucloxicacid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen,ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin,pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen),acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac,diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac,isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, andzomepirac), fenamic acid derivatives (flufenamic acid, meclofenamicacid, mefenamic acid, niflumic acid and tolfenamic acid),biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams(isoxicam, piroxicam, sudoxicam and tenoxican), salicylates (acetylsalicylic acid, sulfasalazine) and the pyrazolones (apazone,bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone);cyclooxygenase-2 (COX-2) inhibitors such as celecoxib; inhibitors ofphosphodiesterase type IV (PDE-IV); antagonists of the chemokinereceptors, especially CCR-1, CCR-2, and CCR-3; cholesterol loweringagents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin andpravastatin, fluvastatin, atorvastatin, and other statins), sequestrants(cholestyramine and colestipol), nicotinic acid, fenofibric acidderivatives (gemfibrozil, clofibrat, fenofibrate and benzafibrate), andprobucol; anticholinergic agents such as muscarinic antagonists(ipratropium bromide); other compounds such as theophylline,sulfasalazine and aminosalicylates, e.g. 5-aminosalicylic acid andprodrugs thereof, antirheumatics.

Antiallergic drugs which are prone to be useful in combination with anmTOR inhibitor, e.g. prone to be useful according to the presentinvention, e.g. include antihistamines (H1-histamine antagonists), e.g.bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine,clemastine, diphenhydramine, diphenylpyraline, tripelennamine,hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine,cyproheptadine, antazoline, pheniramine pyrilamine, astemizole,terfenadine, loratadine, cetirizine, fexofenadine,descarboethoxyloratadine, and non-steroidal anti-asthmatics such asβ2-agonists (terbutaline, metaproterenol, fenoterol, isoetharine,albuterol, bitolterol, salmeterol and pirbuterol), theophylline,cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists(zafirlukast, montelukast, pranlukast, iralukast, pobilukast,SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005);bronchodilators, antiasthmatics (mast cell stabilizers).

In each case where citations of patent applications or scientificpublications are given, the subject-matter relating to the compounds ishereby incorporated into the present application by reference, e.g.comprised are likewise the pharmaceutical acceptable salts thereof, thecorresponding racemates, diastereoisomers, enantiomers, tautomers aswell as the corresponding crystal modifications of above disclosedcompounds where present, e. g. solvates, hydrates and polymorphs, whichare disclosed therein. The compounds used as active ingredients in thecombinations of the invention may be prepared and administered asdescribed in the cited documents or in the product description,respectively. Also within the scope of this invention is the combinationof more than two separate active ingredients as set forth above, i. e. apharmaceutical combination within the scope of this invention couldinclude three active ingredients or more. Further, both the first agentand the co-agent are not the identical ingredient.

The structure of the drug substances identified by code numbers, genericor trade names may be taken from the Internet, actual edition of thestandard compendium “The Merck Index” or from databases, e.g., PatentsInternational, e.g., IMS World Publications, or the publicationsmentioned above and below. The corresponding content thereof is herebyincorporated by reference.

Utility of the mTOR inhibitors in treating endocrine tumors ashereinabove specified, may be demonstrated in vitro, in animal testmethods as well as in clinic, for example in accordance with the methodshereinafter described.

A. In Vitro

A. 1 Antiproliferative Activity in Combination with Other Agents

A cell line, e. g. the Compound A resistant A549 line (IC₅₀ in low nMrange) versus the comparative Compound A resistant KB-31 and HCT116tines (IC₅₀ in the, micromolar range), is added to 96-well plates (1,500cells/well in 100 ul medium) and incubated for 24 hr. Subsequently, atwo-fold dilution series of each compound (an mTOR inhibitor other thanCompound A or a known chemotherapeutic agent) is made in separate tubes(starting at 8× the IC₅₀ of each compound) either alone or in pairedcombinations, and the dilutions are added to the wells.

The cells are then re-incubated for 3 days. Methylene blue staining isperformed on day 4 and the amount of bound dye (proportional to thenumber of surviving cells that bind the dye) determined. IC₅₀s aresubsequently determined using the Calcusyn program, which provides ameasure of the interaction, namely the so-called non-exclusivecombination index (Cl), where:Cl˜1=the interaction is nearly additive;0.85-0.9=slight synergism: <0.85=synergy. In this assay, mTORinhibitors, e.g. the compound A, show interesting antiproliferativeactivity in combination with another chemotherapeutic agent, e.g. suchas defined above, e.g. in combination with somastatin or a somastatinanalogue.

B. In Vitro Assay

The phosphorylation status of downstream markers S6 (the inhibition ofS6K1 activity) is used as a read out, reflecting the immediatepharmacodynamic effect of the mTOR inhibitor, e.g. in the p70S6 kinase 1(S6K1) assay, see e.g. WO2005064343.

Carcionoid efficacy may be determined by measurement of chromogranin Awhich is inter alia hypersecreted in carcionoid cells, see e.g. Davis etal, Gynecology & Obstetrics 1973; 137:637-644.

C. In Vitro Studies

Compound A is able to restore activity of endocrine agents, likeestrogen inhibitors and/or aromatase inhibitors in cells which areotherwise resistant to endocrine agent treatment. Several studies haveimplicated aberrant activity of the Akt kinase as a significantmechanism by which breast cancer tumors are unresponsive to endocrinetherapy.

D. Clinical Trials

In clinical trial studies involving patients having carcinoid or isletcell cancer inhibition of S6K1 activity and a reduction of chromograninA may be observed when administering either Compound A alone, or acombination of Sandostatin LAR® (30 mg daily) and compound A (5 mgdaily). Response evaluation may be performed every 12 weeks. Studyduration: 6 months).

Also synergistic effects of such combination are obtained.

Further clinical studies using Compound A in an amount of 5 mg or 10 mgdaily (5 to 70 mg weekly) in monotherapy, and in combination therapytogether with, e.g. 30 mg, of Sandostatin LAR® daily are investigated,e.g.

A randomized, double-blind, placebo controlled study of compound A in420 patients who are receiving therapy with Sandostatin LAR® foradvanced midgut carcinoid tumors. Patients continue baseline SandostatinLAR® therapy and are randomized to receive Compound A 10 mg/day orplacebo. Primary endpoint is progression free survival (PFS). Secondaryendpoints include overall survival, carcinoid-associated symptoms offlushing and diarrhea, pharmakinetics and pharmadynamics. For efficacyassessment progression and response are assessed per RECIST criteria.Due to the nature of neuroendocrine tumors, all patients must havetriphasic CT scans or MRI. Scans are repeated every two months. Aim:Compound A in combination with Sandostatin LAR® for treatment ofadvanced progressing midgut tumor (carcinoid tumor).

A single-arm placebo controlled study of Compound A 10 mg/day in 100patients with measurable advanced (metastatic or unresentable)pancreatic neuroendcrine tumors (islet cell tumor) after failure ofcytotxic chemotherapy as a monotherapy. Primary goal is to determine theresponse rate. A cohort of 44 patients receiving chronic treatment withSandostain LAR® for secretory pancreatic tumors are also be treated withCompound A, 10 mg a day, in addition to Sandostatin LAR®.

1. A method for treating endocrine tumors, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.
 2. A method for inhibiting growth of endocrine tumors, comprising administering to a subject in need thereof a therapeutical effective amount of an mTOR inhibitor.
 3. A method for inhibiting or controlling endocrine tumors, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.
 4. A method for inducing endocrine tumor regression, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.
 5. A method for treating endocrine tumor invasiveness or symptoms associated with such tumor growth, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.
 6. A method for preventing metastatic spread of endocrine tumors or for preventing or inhibiting growth of micrometastasis, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.
 7. A method for the treatment of a disorder associated with endocrine tumors, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.
 8. A method according to claim 1, comprising administering in addition a therapeutically effective amount of at least one second drug substance.
 9. A method according to claim 8, wherein a second drug substance is somastatin or a somastatin analogue.
 10. The use of an mTOR inhibitor for the manufacture of a medicament for use in a method according to claim
 1. 11. A method according to claim 1, or the use according to claim 10, wherein an mTOR inhibitor is selected from rapamycin or a rapamycin derivative.
 12. A method according to claim 10, wherein an mTOR inhibitor is 40-O-(2-hydroxyethyl)-rapamycin. 